Geron Corporation

LSE:0IV3 Stock Report

Market Cap: US$2.5b

Geron Valuation

Is 0IV3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0IV3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0IV3 ($4.14) is trading below our estimate of fair value ($39.22)

Significantly Below Fair Value: 0IV3 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0IV3?

Key metric: As 0IV3 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0IV3. This is calculated by dividing 0IV3's market cap by their current book value.
What is 0IV3's PB Ratio?
PB Ratio8.4x
BookUS$292.28m
Market CapUS$2.46b

Price to Book Ratio vs Peers

How does 0IV3's PB Ratio compare to its peers?

The above table shows the PB ratio for 0IV3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.6x
GNS Genus
2x37.7%UK£1.1b
AVCT Avacta Group
3.8x-2.1%UK£179.3m
OXB Oxford Biomedica
6.7x93.2%UK£442.5m
SBTX SkinBioTherapeutics
9.9x40.8%UK£36.5m
0IV3 Geron
8.4x72.4%US$2.5b

Price-To-Book vs Peers: 0IV3 is expensive based on its Price-To-Book Ratio (8.4x) compared to the peer average (5.6x).

Price to Book Ratio vs Industry

How does 0IV3's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.47m
VAL ValiRx
0.6xn/aUS$2.79m
No more companies available in this PB range
0IV3 8.4xIndustry Avg. 2.9xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0IV3 is expensive based on its Price-To-Book Ratio (8.4x) compared to the UK Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is 0IV3's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0IV3 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio8.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0IV3's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0IV3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.15
US$7.45
+79.5%
20.0%US$10.00US$5.50n/a10
Nov ’25US$4.13
US$7.17
+73.5%
20.3%US$10.00US$5.50n/a9
Oct ’25US$4.42
US$7.31
+65.6%
20.2%US$10.00US$5.50n/a8
Sep ’25US$4.66
US$7.36
+57.8%
21.4%US$10.00US$5.50n/a7
Aug ’25US$4.77
US$7.29
+52.8%
22.9%US$10.00US$5.00n/a7
Jul ’25US$4.34
US$6.94
+60.0%
26.1%US$10.00US$4.50n/a8
Jun ’25US$3.59
US$6.07
+69.2%
29.3%US$10.00US$4.50n/a7
May ’25US$4.09
US$5.79
+41.5%
30.6%US$10.00US$4.50n/a7
Apr ’25US$3.29
US$5.08
+54.7%
8.8%US$6.00US$4.50n/a6
Mar ’25US$2.28
US$4.75
+108.6%
14.6%US$6.00US$4.00n/a6
Feb ’25US$1.89
US$4.83
+155.7%
14.2%US$6.00US$4.00n/a6
Jan ’25US$2.12
US$4.83
+128.5%
14.2%US$6.00US$4.00n/a6
Dec ’24US$1.95
US$4.83
+148.5%
14.2%US$6.00US$4.00n/a6
Nov ’24US$1.93
US$4.83
+150.7%
14.2%US$6.00US$4.00US$4.136
Oct ’24US$2.12
US$4.83
+128.5%
14.2%US$6.00US$4.00US$4.426
Sep ’24US$2.52
US$4.83
+91.8%
14.2%US$6.00US$4.00US$4.666
Aug ’24US$3.21
US$4.83
+50.7%
14.2%US$6.00US$4.00US$4.776
Jul ’24US$3.23
US$4.83
+49.7%
14.2%US$6.00US$4.00US$4.346
Jun ’24US$3.39
US$4.83
+42.6%
14.2%US$6.00US$4.00US$3.596
May ’24US$2.40
US$4.67
+94.3%
20.2%US$6.00US$3.00US$4.096
Apr ’24US$2.16
US$4.67
+115.8%
20.2%US$6.00US$3.00US$3.296
Mar ’24US$2.75
US$5.33
+93.7%
17.7%US$7.00US$4.00US$2.286
Feb ’24US$3.30
US$5.33
+61.6%
17.7%US$7.00US$4.00US$1.896
Jan ’24US$2.36
US$4.33
+84.0%
31.7%US$7.00US$3.00US$2.126
Dec ’23US$2.26
US$4.33
+91.8%
31.7%US$7.00US$3.00US$1.956
Nov ’23US$2.18
US$4.33
+98.8%
31.7%US$7.00US$3.00US$1.936

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

7D

4.3%

1Y

-21.3%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

7D

1.3%

1Y

13.6%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$745.63

7D

-2.0%

1Y

-6.4%